Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced that… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN) aims to dose first LCA10 patients for CRISPR gene therapy in Q1 2020
REGENXBIO Inc. (Nasdaq: RGNX), a clinical stage gene therapy company, has halted a FDA clinical trial on an AAV anti-VEGF product (RGX-314) for wet AMD… Read More »In follow-up to legal dispute, two commercial trials are halted by FDA on anti-VEGF trials in AMD and diabetic retinopathy
Allergan plc (NYSE: AGN) announced a voluntary recall of its XEN 45 glaucoma drainage device after a small number of units in an unreleased lot… Read More »Allergan issues an urgent device recall for the XEN® Glaucoma Treatment System (XEN® 45 Gel Stent)
Novartis AG (NYSE:NVS; SIX:NOVN) has announced that the U.S. Food and Drug Administration (FDA) has approved brolucizumab (“Beovu”) injection (also known as RTH258) for the… Read More »Novartis announces that FDA brolucizumab injection approves to be noninferior to aflibercept in Phase III studies
Gyroscope Therapeutics Ltd., based in Stevenage, UK, has announced the successful completion of a £50.4 million investment to advance clinical development of an investigational gene… Read More »A UK gene therapy company – Gyroscope Therapeutics Ltd – raises £50.4 million funding for retinal disease treatment
UK researchers in Queens University Belfast (QUB) have published an article on the implications of a “no deal” Brexit for orphan and paediatric medicines. The… Read More »UK researchers highlight negative consequences of Brexit for the development of and access to medicines for orphan (rare) diseases in paediatrics.
A private company, China Ophthalmology Focus Ltd., founded in 2018 and located in Honk Kong has recently raised $50 million in a series A round… Read More »A private company, China Ophthalmology Focus Ltd, is set to focus on the ophthalmic Asia market.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the winners of the seventh annual Regeneron Prize for Creative Innovation. The country’s leading research universities were asked to… Read More »Regeneron Pharmaceuticals Inc. announces the 2019 winners of the “Regeneron Prize for Creative Innovation”
Oxford Biomedica plc (LSE:OXB) and Santen Pharmaceutical Co., Ltd. (Santen) have entered into an R&D collaboration with an option and licence agreement to develop gene… Read More »Oxford Biomedica executes an option and license agreement for gene therapy for inherited retinal disease
Alkahest Inc., a clinical stage biopharmaceutical company based in San Carlos, California, has announced that an experimental drug, AKST4290, in a Phase IIa study for… Read More »Alkahest’s oral small molecule drug aims to report on a Phase IIa study for age-related macular degeneration